Pfizer wins quick reward from buyout of Anacor with approval of eczema drug expected to be blockbuster
Pfizer | December 14, 2016
Score a big win for Pfizer and its $4.5 billion buyout of Anacor Pharmaceuticals. The FDA Wednesday approved Anacor's eczema treatment that is projected to be a $2 billion blockbuster. The FDA approved Eucrisa (crisaborole) ointment to treat mild to moderate atopic dermatitis, better know as eczema, in patients two years and older. The condition results in red, scaly and extremely itchy crusted bumps.